September 18, 2025Frontiers in ImmunologyOpen Access

B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China

View Full Paper

Ask AI

Bookmark

Authors

YXYili Xu LWLiang Wang CJChunming Jiang

Discussion

Member takes

Implication

Prospective cohort study shows lower cost and safety benefits of targeted rituximab therapy in patients with idiopathic membranous nephropathy, suggesting potential for individualized treatment.

Key Points

Individuals receiving B cell- and anti-PLA2R antibody-targeted rituximab therapy achieved remission at a rate of 73.1%.
The overall remission rates for the individualized and standard groups were 74.1% and 70.5%, respectively, with noninferiority demonstrated.
This open-label, prospective cohort study included 140 patients from 10 hospitals in China over nearly 4 years.
The findings support the safety and cost-effectiveness of targeted therapy, highlighting the need for larger randomized trials.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/68d434ea713b0b5dfea7465e https://doi.org/10.3389/fimmu.2025.1633532

View Full Paper

Ask AI

Bookmark

Implication

Prospective cohort study shows lower cost and safety benefits of targeted rituximab therapy in patients with idiopathic membranous nephropathy, suggesting potential for individualized treatment.